SHANGHAI, CHINA----Recently, Viva Biotech signed a new drug discovery technology cooperation agreement with AlphaMa Biotech Co., Ltd. (hereinafter referred to as "AlphaMa"). According to the agreement, Viva Biotech will cooperate with AlphaMa on innovative drug discovery technology to provide clients with the new generation of AI-based DNA coding compound library (Intelligent DEL, iDEL) screening technology platform for lead generations for a series of specific targets in the field of neurological, autoimmune and other diseases.
Viva Biotech and AlphaMa Reached Cooperation Agreement on IntelligentDEL (iDEL)
December 22, 2020
Previous article :